A new research paper was published in Oncotarget’s Volume 14 on December 20, 2023, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.”
No Kidney Benefit With Finerenone in Heart Failure Patients
SAN DIEGO — Finerenone (Kerendia) yielded minimal renal benefit in patients with heart failure with mildly reduced or preserved ejection fraction, according to a secondary
October 29, 2024